Haemonetics (STU:HAZ) Total Equity: €689 Mil (As of Mar. 2026)


STU:HAZ Haemonetics Corp STU:HAZ
79 GF Score
Price €65.00
GF Value €73.57
! 4 Warning Signs
View Full Analysis

What is Haemonetics Total Equity?

Haemonetics STU:HAZ -0.76% 79 Total Equity is €689 Mil as of Mar. 2026. GuruFocus rates STU:HAZ with a GF Score™ of 79/100 and a GF Value™ of €73.57. The stock has 4 warning signs investors should review.

Haemonetics's total equity for the quarter that ended in Mar. 2026 was €689 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Haemonetics Total Equity Historical Data

* Premium members only.

The historical data trend for Haemonetics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Haemonetics Total Equity Chart

Haemonetics Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 680.48 764.01 883.16 759.27 688.82

Haemonetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 759.27 764.95 723.50 778.38 688.82
STU:HAZ
79GF Score
Haemonetics Corp STU:HAZ
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Haemonetics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Haemonetics's Total Equity for the fiscal year that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=2072.475-1383.658
=689

Haemonetics's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=2072.475-1383.658
=689

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of €689 Mil mean?
Haemonetics (STU:HAZ) has a Total Equity of €689 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Haemonetics and its competitors.
Is Haemonetics' Total Equity too high?
Haemonetics' current Total Equity is €689 Mil. Overall, Haemonetics has a GF Score™ of 79/100, reflecting its overall financial health beyond just this single metric.
How does Haemonetics' Total Equity compare to ITGR and IRTC?
Haemonetics' Total Equity of €689 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Medical Devices & Instruments company?
A good Total Equity depends on the Medical Devices & Instruments industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Haemonetics and its competitors. Haemonetics's current Total Equity is €689 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Haemonetics stock overvalued right now?
Haemonetics (STU:HAZ) has a current Total Equity of €689 Mil. The stock's GF Value™ is €73.57, compared to a current price of €65.00 — trading 11.6% below its estimated fair value. The current Total Equity is €689 Mil. Haemonetics' overall GF Score™ is 79/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Haemonetics (STU:HAZ), the current Total Equity is €689 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Haemonetics (STU:HAZ) Overvalued in 2026?

Based on GuruFocus' analysis, Haemonetics stock appears to be undervalued. The current stock price of €65.00 is trading 11.6% below its estimated GF Value™ of €73.57.

Key valuation signals for STU:HAZ:

  • Total Equity: €689 Mil
  • GF Value™: €73.57 vs. price of €65.00 (11.6% below fair value)
  • GF Score™: 79/100 with 4 warning signs

No single metric tells the full story. See the STU:HAZ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Haemonetics Business Description

Other Exchanges HAE:USA
Address 125 Summer Street, Boston, MA, USA, 02110
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
79GF Score

Get the complete analysis for STU:HAZ

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€65.00
Price
€73.57
GF Value